Anixa-MolGenie compounds are more potent than the protease inhibitor in Pfizer’s PAXLOVID™ at inhibiting the main protease of SARS-CoV-2

SAN JOSE, Calif. and STUTTGART, Germany, Jan. 24, 2022 /PRNewswire/ — Anixa Biosciences, Inc. (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer and infectious diseases, today announced that the company and its partner, MolGenie GmbH, have synthesized a compound that appears to be considerably more potent than nirmatrelvir at inhibiting Mpro, the main protease of the SARS-CoV-2 virus. Nirmatrelvir is the main component of Pfizer’s PAXLOVID™, which was recently authorized to treat COVID-19. PAXLOVID also includes ritonavir, which is an HIV drug.

Consent Management Platform by Real Cookie Banner